---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-036386"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:26:30.732001+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alumis Phase 3 envudeucitinib hits PASI 90/100 endpoints in plaque psoriasis

## Summary
- PASI 90 at Week 24: 68.0% (ONWARD1) and 62.1% (ONWARD2); PASI 100: 41.0% and 39.5%.
- Early onset: PASI 90 separation vs placebo by Week 4; itch relief by Week 2; scalp clearance in ~30% by Week 4.
- Safety profile consistent with Phase 2; no new signals, mainly mild AEs (headache, nasopharyngitis, URTI, acne).
- Company to submit NDA to FDA in H2 2026; Phase 3 long-term extension (ONWARD3) ongoing.
- Also evaluating envudeucitinib in SLE LUMUS Phase 2b with topline data expected Q3 2026.

## SEC filing metadata
- accession: 0001104659-26-036386
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/0001104659-26-036386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-036386
- JSON: https://secwatch.observer/filing/0001104659-26-036386.json
- Plain text: https://secwatch.observer/filing/0001104659-26-036386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.